Drug Repurposing for SARS-CoV-2 Infection Using Human Organoid Culture Technology

04/22/2020
Drug Repurposing for SARS-CoV-2 Infection Using Human Organoid Culture Technology
In the search for drugs effective against SARS-CoV-2 infection, there are speed and safety advantages to repurposing existing drugs. This project will test thousands of FDA-approved drugs and other clinical-stage compounds alone and in combination with each other to see how effective they are in combating SARS-CoV-2 infections. The most promising potential therapies will be evaluated on a state-of-the-art human airway cell platform developed with collaborator and local biotech leader STEMCELL Technologies, and tested for their ability to inhibit all stages of the virus lifecycle. This project could catalyze the discovery of desperately needed candidate therapeutics for COVID-19. It also leverages the virology, drug discovery, and protein analysis expertise of an interdisciplinary, international team to create a consortium well-positioned to rapidly identify lead therapeutic candidates for emerging pathogens.

  • Project Leaders: Francois Jean
  • Institutions: University of British Columbia (UBC)
  • Budget: $250000
  • Competition: Rapid Response Funding for COVID-19 Research Projects
  • Genome Centre(s): Genome British Columbia
  • Fiscal Year: 2020
  • Status: Active

Source: Genome BC

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.